MARTINE RAYMOND, Ph.D.
- Principal Investigator,
Yeast Molecular Biology research unit, Institute for Research in Immunology and Cancer
- Full Professor, Department of Biochemistry, Faculty of Medicine, Université de Montréal
- Accredited Member, Molecular Biology Programs, Faculty of Medicine, Université de Montréal
- Adjunct Member, Departments of Experimental Medicine, McGill University
AWARDS & HONOURS
- Senior Scholar, Fonds de la recherche en santé du Québec, 2002-2006
- Junior Scholar, Fonds de la recherche en santé du Québec, 1999-2002
- Scholar, Medical Research Council of Canada, 1994-1999
TRAINING
- Postdoctoral training with David Thomas, Biotechnology Research Institute, National Research Council of Canada, 1990-1994
- Ph.D. in Biochemistry with Philippe Gros, McGill University, 1984-1990
RESEARCH SUPPORT
- Canadian Institutes of Health Research
Martine Raymond is interested in the molecular mechanisms of multidrug resistance. Trained as a biochemist, Dr. Raymond joined the Institute for Research in Immunology and Cancer (IRIC) in 2005, after eleven years as an independent researcher at the
l’Institut de recherches cliniques de Montréal. Her research uses the yeast Candida albicans as a model.
The cell membrane contains transport proteins that translocate cytotoxic compounds toward the exterior of the cell. In a research project on the mechanisms of resistance to antifungal drugs, Dr. Raymond is studying the function of transporters of the ABC (ATP-binding cassette) family in C. albicans. Her work also focuses on the involvement of phospholipid transfer proteins in this resistance.
Her second project focuses on the functional genomics of C. albicans. Her team participated in the annotation of the C. albicans genome, a project led by a group from the Biotechnology Research Institute (BRI) of the National Research Council of Canada. Working jointly, the two groups are using the inTRAINING from the annotation project to produce DNA chips and identify the transcriptional networks that control metabolism, hypoxia, as well as virulence processes and multiple drug resistance in this yeast.
In addition, Dr. Raymond seeks to identify new proteins involved in the ubiquitination process or modification of chromatin and likely to constitute therapeutic targets for the development of new drugs. As part of a collaboration with the team of Dr. Alain Verreault, these researchers showed that the protein Hst3, a deacetylase for histone H3-specific yeast, is essential for growth and virulence of C. albicans. These results constitute a first step in the development of new antifungal therapies that target chromatin.
SELECTED PUBLICATIONS
Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aïd M, Boucher G, Rogers PD, Raymond M, Morschhäuser J (2011) Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother 55:2212-2223.
Wurtele H, Tsao S, Lépine G, Mullick A, Tremblay J, Drogaris P, Lee EH, Thibault P, Verreault A, Raymond M. (2010) Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat Med. Jul;16(7):774-80. Epub 2010 Jul 4.
Epp E, Walther A, Lépine G, Leon Z, Mullick A, Raymond M, Wendland J, Whiteway M (2010) Forward genetics in Candida albicans reveals the Arp2/3 complex is required for hyphal formation but not endocytosis. Mol Microbiol 75:1182-1198.
Znaidi S, Barker KS, Weber S, Alarco AM, Liu TT, Boucher G, Rogers PD, Raymond M (2009) Identification of the Candida albicans Cap1p regulon. Eukaryot Cell 8:806-820.
Trunk K, Gendron P, Nantel A, Lemieux S, Roemer T, Raymond M (2009) Depletion of the cullin Cdc53p induces morphogenetic changes in Candida albicans. Eukaryot Cell 8:756-767.
Tsao S, Rahkhoodaee F, Raymond M (2009) Relative contribution of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother 53:1344-1352.
Znaidi S, Weber S, Zin Al-Abdin O, Bomme P, Saidane S, Drouin S, Lemieux S, De Deken X, Robert F, Raymond M (2008) Genome-wide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot Cell 7:836-847.
Znaidi S, De Deken X, Weber S, Rigby T, Nantel A, Raymond M (2007) The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol Microbiol 66:440-452
Saidane S, Weber S, De Deken X, St-Germain G, Raymond M (2006) PDR16-mediated azole resistance in Candida albicans. Mol Microbiol 60:1546-1562
Braun BR, van Het Hoog M, d'Enfert C, Martchenko M, Dungan J, Kuo A, Inglis DO, Uhl MA, Hogues H, Berriman M, Lorenz M, Levitin A, Oberholzer U, Bachewich C, Harcus D, Marcil A, Dignard D, Iouk T, Zito R, Frangeul L, Tekaia F, Rutherford K, Wang E, Munro CA, Bates S, Gow NA, Hoyer LL, Kohler G, Morschhauser J, Newport G, Znaidi S, Raymond M, Turcotte B, Sherlock G, Costanzo M, Ihmels J, Berman J, Sanglard D, Agabian N, Mitchell AP, Johnson AD, Whiteway M, Nantel A (2005) A human-curated annotation of the Candida albicans genome. PLoS Genet 1:36-57
Top
<< Back to Investigators List
